An interventional study of Serial measurements of NT-pro BNP, potassium, sodium, and creatinine every second business day in Acute Decompensated Heart Failure, sponsored by Prof. Dr. Jörg Leuppi. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-17.
Sponsored by Prof. Dr. Jörg Leuppi · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 149 studies in Heart Failure with a site in Switzerland — 21 open to participants now, 32 under way, 1 of them phase 3. Heart Failure · Switzerland.
Among the 149 studies in Heart Failure with a site in Switzerland, this one is the 77th largest by enrollment of the 100 interventional ones that give a count, is one of 9 that started in 2018, is one of 50 with no phase, and was the 119th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →21 of the 149 studies in Heart Failure with a site in Switzerland are open now. Recruiting first, the newest first:
Biotronik SE & Co. KG · Sites in Switzerland, Australia, Austria and 10 more countries
Ages 18+
Fondazione Don Carlo Gnocchi ETS · Sites in Switzerland, Belgium, Italy and 1 more country
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland, Australia, Bulgaria and 4 more countries
Ages 18+
University Hospital, Basel, Switzerland · Sites in Switzerland, Austria, Bulgaria and 6 more countries
Ages 65+
Bayer · Sites in Switzerland, Austria, Belgium and 14 more countries
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 25 · Phase 4 17
First in 1983; this study’s year is marked. 9 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 314 across the 100 interventional studies, 589 across the 46 observational. Of the 105 that completed or were terminated, 38 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 149 have an industry lead sponsor. The 10 most frequent:
Prof. Dr. Jörg Leuppi is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Prof. Dr. Jörg Leuppi has 2 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
7 of the studies in Heart Failure with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02444416Sebastian CarballoProspective Registry of Acute Heart Failure | 2026-11 |
| NCT06942221University Hospital, Basel, SwitzerlandDigital Solutions in Heart Therapy (DIGNITY) | 2026-12-31 |
| NCT07319039University Hospital, GenevaBreathlessness Patterns in Patients With Cancer, COPD and Heart Failure: an fMRI Feasibility Study | 2027-03-01 |
| NCT06465498Antonio LeidiInvestigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography | 2027-04-30 |
| NCT07852221Insel Gruppe AG, University Hospital BernPatient Selection and Long-Term Outcomes of Pace & Ablate Strategy in Atrial Fibrillation | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 149 studies in Heart Failure with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to explore whether the availability of serial NT-proBNP measurements together with safety parameters such as electrolytes and creatinine may influence treatment decision in patients with acute decompensated heart failure (ADHF) leading to more rapid and faster dose increase of prognostic therapies and earlier hospital discharge.
The proposed study is a prospective, unblinded, single center, 2-arm randomized controlled pilot trial. In the intervention arm serial measurement of NT-proBNP will be made available to the treating physician. A control group continuing to undergo care according to the 2016 ESC Guidelines will serve as comparator. Changes in NT-proBNP levels, safety laboratory parameters such as sodium, potassium, creatinine, Heart failure (HF) medication, vital signs, body weight and BMI, Quality of Life (QoL), length of hospital stay, New York Heart Association (NYHA) functional class, adverse events, transfer to the Intensive Care Unit and mortality will be recorded in patients with ADHF.
The Kantonsspital Baselland (KSBL) Liestal will be the only study center. All members of the study group will the thoroughly instructed regarding study procedures. Inclusion visits will be conducted only by a member of the study group. All Patients with ADHF on the medical ward of the KSBL Liestal will be provided an information sheet regarding goals and procedures of the study and the informed consent. Inclusion criteria will be checked after admission. Patients not matching the inclusion criteria at the screening visit cannot participate in this study. Patients will be provided sufficient time for their decision. The investigators communicate clearly that participation in the study is absolutely voluntary and refusal of participation has no influence on treatment during hospitalization.
In order to minimize bias that may be introduced by even minor differences in executing and interpreting technical exams, all study related measurements and procedures will be performed in a centralized manner at the KSBL Liestal.
Patients will be included only after approval of informed consent. Randomization is performed using 50 closed envelopes containing a paper shit with either the letter A or B. In total there are 25 A's and 25 B's. The letter A stands for the control group and the letter B for the intervention group. These envelopes are mixed initially, numbered for order purposes and the order maintained throughout the study. The name of the patient will be written down on the envelope. Then it will be open and the patient will be allocated to the study group depending on the letter in the envelope. All patients will undergo an inclusion and discharge visit. General demographic data, including age, gender, nationality, smoking status, alcohol consumption, current profession, exercise behavior, allergies, medication, HF history and comorbidities will be recorded. Assessment of vital signs and body weight will be performed together with an electrocardiogram, several laboratory tests (NT-proBNP, potassium, sodium and creatinine). In addition, questionnaires concerning QoL (SF-12, KCCQ, MLWHFQ) will be filled in by the participants. Women who can get pregnant (not yet in menopause and last menstrual period less than 12 months, not surgically sterilized, ovaries and/or uterus not removed) will have to undergo a pregnancy test prior to inclusion into the study.
Patients allocated to the intervention group (POC-available group) will undergo serial measurements of NT-pro BNP, potassium, sodium, and creatinine every second business day. The investigators have chosen this time-lag because an earlier time point would not show the change of the security parameter creatinine due to longer half-life-time. For this test, blood is collected from the patients. These samplings will be done in the morning together with the regularly blood collection through the attending nurse according to the established procedure of the KSBL Liestal in the morning. 10ml blood will be collected for this study during each blood sample with a standard Lithium-blood-collection tube. Members of the study team will collect the blood samples and analyses them on the study devices. The result of the test will be provided directly to the responsible physician of the medical department at the KSBL Liestal. Treatment changes are at the discretion of the responsible physician. The physician will be alerted by a phone call of a study member if the NT-proBNP hasn't decreased by 10% or more between two measurements. But no specific recommendations with regards to therapy will be provided by the investigator or his team. However, diagnostic and therapeutic decisions will be based on the current 2016 ESC guidelines on the diagnosis and therapy of HF as established at the KSBL Liestal.
Patients allocated to the control group will undergo the measurements at inclusion and discharge visit. The control group conduces to compare the NT-proBNP and HF medication changes under therapy monitoring with serial NT-proBNP measurements to the NT-proBNP and HF medication changes with sign and symptom guided HF therapy. As in the intervention group, diagnostic and therapeutic decisions in the control group will be based on the current 2016 ESC guidelines on the diagnosis and therapy of HF as established at the KSBL Liestal. At discharge, the same measurements as at the inclusion visit will be repeated in all patients to monitor the effects associated with the participation in this trial.
Total study duration will cover a period of approximately 3 years. Patients will be screened until a total of 25 patients are included per study group.
Overall, 50 patients are planned to be recruited. Recruitment is estimated to start in September 2017 and end at the latest in March 2020 after discharge of the last hospitalized patient included in the study. Data collection of the study is expected to be completed by May 2020 and data analysis by December 2020.
The expected duration of the study for each patient will be defined by the time period from inclusion to discharge and is expected to be in the range of 8-12 days (=average time for HF hospitalization of our institution).
As an university institution, the KSBL Liestal mandates its physician and nursing staff to provide evidence-based medical care and to follow recognized and established national and/or international guidelines whenever possible. Nevertheless, deviation from guidelines may be necessary in specific cases. The decision whether and when to deviate from guidelines is at the discretion of the responsible physician and nursing staff and is taken to the best individual knowledge. Patients with ADHF admitted to the Intensive Care Unit are not included in this study. Patients not requiring intensive care treatment will be hospitalized on a regular medical ward and treated with diuretics to improve symptoms of congestion. In case a patient is transferred to the Intensive Care Unit after study inclusion, further data from date of transfer onwards will not be collected, to avoid discomfort to patients and medical personal while the patient is in a critical situation. The study itself is also composed for treatments on a regular medical ward. The transfer to the Intensive Care Unit will serve as the endpoint.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
E.g.: Dyspnea Paroxysmal nocturnal dyspnea Reduced exercise capacity Fatigue Extended recovery after exercising Peripheral edema (lower leg, ankle) NT-proBNP >300 (pg/ml)
Exclusion Criteria:
On-going cancer treatment
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group A: Patients allocated to the control group will undergo the measurements at inclusion and discharge visit. The control group conduces to compare the NT-proBNP and HF medication changes under therapy monitoring with serial NT-proBNP measurements to the NT-proBNP and HF medication changes with sign and symptom guided HF therapy. The diagnostic and therapeutic decisions in the control Group and in the Intervention group will be based on the current 2016 ESC guidelines on the diagnosis and therapy of HF as established at the KSBL Liestal. At discharge, the same measurements as at the inclusion visit will be repeated in all patients to monitor the effects associated with the participation in this trial.
Group B:Patients allocated to the intervention group (POC-available group) will undergo serial measurements of NT-pro BNP, potassium, sodium, and creatinine every second business day. The blood collection (10 ml of Lithium Heparin blood) for these tests will be done in the morning together with the regularly blood collection. The study team does the the analysis on the study devices. The result of the test will be provided directly to the responsible physician. Treatment changes are at the discretion of the responsible physician. The physician will be alerted by a phone call of a study member if the NT-proBNP hasn't decreased by 10% or more between two measurements. But no specific recommendations with regards to therapy will be provided by the investigator or his team. However, diagnostic and therapeutic decisions will be based on the current 2016 ESC guidelines on the diagnosis and therapy of HF as established at the KSBL Liestal.
Other: Serial measurements of NT-pro BNP, potassium, sodium, and creatinine every second business day
Serial measurements of NT-proBNP, sodium, potassium, and creatinine in the NT-proBNP-group vs. no serial measurements in control group. In the intervention group the body weight, vital parameters, therapy changes and adverse events are documented the above mention serial measurement every second business day.
Changes in NT-proBNP
Meassurement of NT-proBNP
Time frame: Up to 4 weeks, on average 10 days
Dosage and variations in medication to treat heart failure
Changes in medical heart failure therapies such as Diuretics, Nitrates, Angiotensin-converting-enzyme (ACE) Inhibitors or angiotensin-receptor blockers (ARBs), Beta blocker
Time frame: Up to 4 weeks, on average 10 days
HR (in beats/min)
Vital signs
Time frame: Up to 4 weeks, on average 10 days
BP (in mmHg)
Vital sign
Time frame: Through study completion, on average 10 days
BMI and Body weight
Body mass index and weight in kg
Time frame: Up to 4 weeks, on average 10 days
KCCQ (Kansas City Cardiomyopathy ) Questionnaire
The KCCQ is a self-administered, 23-item questionnaire measuring HRQoL in patients with CHF regardless of its origin. Each item has a 5-, 6-, or 7-point Likert scale. The questionnaire assesses six domains of HRQoL: Physical Limitation, Symptoms, Symptom Stability, Social Limitation, Self-Efficacy, and Quality of Life. Domain scores were transformed to 0-100 (highest level of functioning) scales.
Time frame: Up to 4 weeks, on average 10 days
SF12 (Short Form 12 Health Survey ) Questionnaire
A mental component score (MCS-12) and a physical component score (PCS-12). The scores may be reported as Z-scores (difference compared to the population average, measured in standard deviations). The United States population average PCS-12 and MCS-12 are both 50 points. The United States population standard deviation is 10 points. So each 10 increment of 10 points above or below 50, corresponds to one standard deviation away from the average.
Time frame: Up to 4 weeks, on average 10 days
Minnesota LIVING WITH HEART FAILURE® Questionnaire
The questionnaire is comprised of 21 important physical, emotional and socioeconomic ways heart failure can adversely affect a patient's life. After receiving brief standardized instructions, the patient marks a 0 (zero) to 5 scale to indicate how much each itemized adverse of heart failure has prevented the patient from living as he or she wanted to live during the past 4 weeks. The questionnaire is simply scored by summation of all 21 responses. The instrument can be used as a key outcome measure in studies and evaluations of outpatients with symptomatic (NYHA class II to IV) heart failure with a reduced or preserved ejection fraction. This patient-reported outcome can be used to determine whether a treatment for heart failure is effective for improving patients' quality of life by reducing the adverse impact of heart failure.
Time frame: Up to 4 weeks, on average 10 days
Potassium
Meassurement of potassium as safety parameter
Time frame: Up to 4 weeks, on average 10 days
Sodium
Meassurement of sodium as safety parameter
Time frame: Up to 4 weeks, on average 10 days
Creatinine
Meassurement of creatinine as safety parameter
Time frame: Up to 4 weeks, on average 10 days
Length of hospital stay
Days spent in the hospital
Time frame: Up to 4 weeks, on average 10 days
NYHA functional class
NYHA class I-IV
Time frame: Up to 4 weeks, on average 10 days
Transfer to the Intensive Care Unit (ICU)
Stay at ICU
Time frame: Number pf patients
Ran from Jan 2018 to primary completion in May 2020, 27 months.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's 27 months is close to that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Prof. Dr. Jörg Leuppi